Publications
A. Journal Articles
1. Ezdinli EZ, Nanus DM. B-lymphoproliferative disorders: A proposed unified pathogenetic pathway. Hematol Oncol 1983;1:297-319.
2. Nanus DM, Kelsen D, Clark D. Radiation induced angiosarcoma. Cancer 1987;60:777-779.
3. Nanus DM, Kelsen DP, Lipperman R, Eisenberger M. Phase II trial of ifosfamide in epidermoid carcinoma of the esophagus: Unexpectant severe toxicity. Inv New Drugs1988;6:239-241.
4. Nanus DM, Ebrahim SAD, Bander NH, Real FX, Pfeffer LM, Shapiro JR, Albino AP. Transformation of human kidney proximal tubule cells by ras-containing retroviruses: Implications for tumor progression. J Exp Med 1989;169:953-973.
5. Nanus DM, Kelsen DP, Niedzwiecki D, Chapman D, Brennan M, Melamed M. Flow cytometry as a predictive indicator in patients with operable gastric cancer. J Clin Onc 1989;7:1105- 1112.
6. Albino AP, Nanus DM, Mentle IR, Cordon-Cardo C, McNutt S, Bressler J, Andreeff M. Analysis of ras oncogenes in malignant melanoma and precursor lesions: Correlation of point mutations with differentiation phenotype. Oncogene, 1989;4:1363-1374.
7. Nanus DM, Mentle IR, Motzer RJ, Bander NH, Albino AP. Infrequent point mutations of ras oncogenes in renal cell carcinoma. J Urol 1990;143:175-178.
8. Nanus, DM, Kelsen DP, Mentle IR, Altorki N, Albino AP. Infrequent Point Mutations of ras Oncogenes in Gastric Cancers. Gastroenterology 1990;98:955-960.
9. Dmitrovsky E, Murty VVVS, Moy D, Miller WH, Nanus D, Albino AP, Samamiego F, Bosl G, Chaganti RSK. Isochromosome 12p in non-seminoma cell lines: Karyologic amplification of c-Ki-ras2 without point-mutational activation. Oncogene 1990;5:543-548.
10. Nanus DM, Pfeffer LM, Bander NH, Bahri S, Albino AP. Anti-proliferative and antitumor effects of alpha interferon in renal cell carcinomas: Correlation with the expression of a kidney associated differentiation glycoprotein. Cancer Res 1990;50:4190-4194.
11. Volkenandt M, Schlegel U, Nanus DM, Albino AP. Mutational analysis of the human p53 gene in malignant melanoma. Pigment Cell Res 1991;4:35-40.
12. Albino AP, Nanus DM, Davis ML, Mcnutt S. Lack of evidence for ki-ras codon 12 mutations in melanocytic lesions. J Cutaneous Path 1991;18:273-278.
13. Albino AP, Davis BM, Nanus DM. Induction of growth factor RNA expression in human malignant melanoma: Markers of transformation. Cancer Res 1991;51:4815-4820.
14. Eisenkraft BL, Nanus DM, Albino AP, Pfeffer LM. -Interferon downregulates epidermal growth factor receptors on renal carcinoma cells: Relation of cellular responsiveness to the antiproliferative action of -interferon. Cancer Res 1991;51:5881-5887.
15. Nanus DM, Lynch SA, Rao PH, Anderson SM, Jhanwar SC, Albino AP. Transformation of human kidney proximal tubule cells by src-containing retroviruses. Oncogene 1991;6:2105- 2111.
16. Pfeffer LM, Eisenkraft BL, Nanus DM, Bander NH & Albino AP. The anti-proliferative and antitumor effects of alpha-interferon on cultured renal carcinomas correlate with the expression of a kidney-associated differentiation antigen. Interferons and Cytokines 1991;17:30-31.
17. Ilson DH, Motzer RJ, Kradin R, Vogelzang NJ, Bajorin D, Scher H, Nanus D, O'Moore P, Marathias K, Bosl GJ. A phase II trial of interleukin-2 and interferon-alpha in patients with advanced renal cell carcinoma. J Clin Onc 1992;10:1124-1130.
18. Motzer RJ, Nanus DM, O'Moore P, Scher HI, Bajorin DF, Reuter V, Tong WP, Iversen J, Louison C, Albino AP, Bosl GJ. A phase II trial of suramin in patients with advanced renal cell carcinoma: Treatment results, pharmacokinetics and tumor growth factor expression. Cancer Res 1992;52:5775-5779.
19. Albino AP, Sozzi G, Nanus DM, Jhanwar S, Houghton A.N. Complete transformation of human melanocytes by infection with a retrovirus containing the viral Ha-ras oncogene and resulting genetic instability. Oncogene 1992;7:2315-2321.
20. Rusch VW, Reuter VE, Kris MG, Kurie J, Miller WH, Nanus DM, Albino AP, Dmitrovsky E. ras Oncogene point mutation: An infrequent event in bronchioalveolar cancer. J Thorac Cardiovasc Surg 1992;104:1465-1469.
21. Nanus DM, Engelstein D, Gastl GA, Gluck L, Vidal MJ, Morrison M, Finstad CL, Bander NH, Albino AP. Molecular cloning of the human kidney differentiation antigen gp160: Human aminopeptidase A. Proc Natl Acad Sci USA 1993;90:7069- 7073.
22. Gastl GA, Abrams JS, Nanus DM, Oosterkamp R, Silver J, Liu F, Chen M, Albino AP, Bander NH. Interleukin-10 production by human carcinoma cell lines and its relationship to interleukin-6 expression. Int J Cancer 1993;55:96-101.
23. Loganzo F, Dosik JS, Zhao Y, Vidal MJ, Nanus DM, Sudol M, Albino AP. Elevated expression of protein tyrosine kinase c-yes, but not c-src, in human malignant melanoma. Oncogene 1993;8:2637-2644.
24. Nanus DM, Schmitz-Drager BJ, Motzer RJ, Lee AC, Vlamis V, Cordon-Cardo C, Albino AP, Reuter VE. Expression of basic fibroblast growth factor in primary human renal tumors: Correlation with poor survival. J Natl Cancer Inst 1993;85:1597-1599.
25. Albino AP, Vidal M, McNutt NS, Shea C, Prieto V, Nanus DM, Palmer JM, Hayward NK. Mutation and expression of the p53 gene in human malignant melanoma. Melanoma Res 1994;4:35-35.
26. Motzer RJ, Schwartz P, Murray-Law T, Hoffman AD, Albino AP, Vlamis V, Nanus DM. Antitumor Effect of interferon alfa-2a and 13 cis-retinoic Acid in renal cell carcinoma: Results of a Phase II Trial and in vitro Studies. J Clin Onc 1995;13:1950-57.
27. Scher HI, Zhang ZF, Nanus D, Kelly WK. Hormone and antihormone withdrawal: Implications for the management of androgen-independent prostate cancer. Urology 1996;47:61-69.
28. Hoffman AD, Engelstein D, Bogenrieder T, Papandreou C, Steckelman E, Motzer RJ, Dmitrovsky E, Albino AP, Nanus DM. Expression of retinoid acid receptor beta correlates with sensitivity to the antiproliferative effects of retinoic acid in human renal cell carcinomas. Clin Cancer Res 1996;2:1077-1082.
29. Presti JC, Reuter VE, Cordon-Cardo C, Albino AP, Jhanwar SC, Nanus DM. Expression of the retinoblastoma gene product in renal tumors. Anticancer Res 1996;16:549-556.
30. Papandreou CN, Bogenrieder T, Scher HI, Albino AP, Nanus DM. Expression and sequence analysis of the SD11/WAF1/CIP1/p21 tumor suppressor gene in prostate cancer cell lines. Int J Oncol 1996;8:1237-1241.
31. Papandreou C, Bogenrieder T, Loganzo F, Chao MV, Nanus DM, Albino AP. Mutation and expression of the low affinity nerve growth factor receptor in human malignant melanoma. Melanoma Res 1996;6:373-378.
32. Motzer RJ, Bander NH, Nanus DM. Renal cell carcinoma. N Engl J Med 1996;335:865-875.
33. Pfeffer LM, Wang C, Constantinescu SN, Croze E, Blatt LM, Albino AP, Nanus DM. Human renal cancers resistant to interferon's antiproliferative action exhibit sensitivity to IFN's gene-inducing and antiviral actions. J Urol 1996;156:1867-1871.
34. Hardy DO, Scher HI, Bodenreider T, Sabbatini P, Zhang Z-F, Nanus DM, Catterall JF. Androgen receptor CAG repeat lengths in prostate cancer: Correlation with age of onset. J Clin Endo Metab 1996;81:4400-4405.
35. Papandreou CN, Bogenrieder T, Loganzo F, Albino AP, Nanus DM. Expression and sequence analysis of the p21(WAF1/CIP1) gene in renal cancers. Urology 1997;41:481-486.
36. Bogenrieder T, Finstad CL, Freeman R, Reuter VE, Papandreou C, Scher HI, Albino AP, Nanus DM. Expression and localization of aminopeptidase A, aminopeptidase N, and dipeptidyl peptidase IV in human benign and malignant prostate tissue. Prostate 1997;33:225-232.
37. Berg WJ, Schwartz LH, Amsterdam A, Mazumdar M, Murray-Law T, Vlamis V, Nanus DM, Motzer RJ. Clinical studies with 13-cis-retinoic acid in patients with advanced renal cell carcinoma. Inv New Drugs 1997:15;353-355.
38. Papandreou CN, Usmani B, Geng Y, Bogenrieder T, Freeman R, Wilk S, Finstad CL, Reuter VE, Powell CT, Scheinberg D, Magill C, Scher HI, Albino AP, Nanus DM. Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen- independent progression. Nature Med 1998;4;50-57.
39. Geng Y, Biffi A, Engelstein D, Ronchi E, Faustini M, Lai H-K, Albino AP, Di Fronzo G, Nanus DM. Expression of the kidney-associated differentiation glycoprotein gp160 and resistance to the antitumor effects of interferon in renal cell carcinomas. Anticancer Res 1998:18;1-8.
40. Nanus DM, Bogenrieder T, Papandreou CN, Finstad CL, Lee A, Vlamis V, Motzer RJ, Bander NH, Albino AP, Reuter VE. Aminopeptidase A expression and enzymatic activity in primary human renal cancers. Int J Oncol 1998:13;261-267.
41. Papandreou CN, Bogenrieder T, Finstad CL, Freeman RH, Chao MV, Albino AP, Scher HI, Reuter VE, Nanus DM. Reversal of the low affinity neurotrophin receptor stromal-epithelial expression pattern between benign and malignant human prostate. Urologic Oncol 1998:4;210-217. .
42. Nanus DM. Decision to operate, radiate or watch and wait: the prostate cancer dilemma. Cancer
Inv 1999:17;374-375.
43. Berg WJ, Nanus DM, Leung A, Brown KT, Hutchinson B, Vlamis V, Mazumdar M, Xu X-C, Lotan R, Reuter VE, Motzer RJ. Up-regulation of retinoic acid receptor- expression in renal cancers in vivo correlates with response to 13-cis-retinoic acid and interferon -2a. Clin Cancer Res 1999:5;1671-1675
44. Usmani BA, Janeczko M, Mazumdar M, Shen R, Papandreou CP, Nanus DM. Analysis of the insertion/deletion polymorphism of the human angiotensin converting enzyme (ACE) gene in patients with renal cell carcinoma. Br J Cancer 2000:82;550-2.
45. Kelly WK, Osman I, Reuter VE, Curley T, Heston WDW, Nanus DM, Scher HI. The development of biologic endpoints in patients treated with differentiation agents: An experience of retinoids in prostate cancer: Clin Cancer Res 2000:6;838-846.
46. Shen R, Sumitomo M, Dai J, Harris A, Kaminetzky D, Gao M, Burnstein KL, Nanus DM. Androgen-induced growth inhibition of androgen receptor expressing androgen- independent prostate cancer cells is mediated by increased levels of neutral endopeptidase. Endocrinology 2000:141;1699-1704.
47. Usmani BA, Shen R , Janeczko M, Papandreou CN, Lee W-H, Nelson WG, Nelson JB, Nanus DM. Methylation of the neutral endopeptidase gene CpG island in human prostate cancer. Clin Cancer Res, 2000:6;1664-70.
48. Motzer RJ, Murphy BA, Bacik J, Schwartz LH, Nanus DM, Mariani T, Loehrer P, Wilding G, Fairclough DL, Cella D, Mazumdar M. Phase III trial of interferon alfa-2a with or without 13-cis retinoic acid for patients with advanced renal cell carcinoma. J Clin Onc 2000:18;2972-2980.
49. Nanus DM, Geng Y, Shen R, Lai HK, Pfeffer SR, Pfeffer LP. Interaction of retinoic acid and interferon in renal cancer cell lines. J Interferon Cytokine Res 2000:20;87-94.
50. Sumitomo M, Shen R, Walburg M, Dai J, Geng Y, Navarro D, Boileau G, Papandreou CN, Giancotti FG, Knudsen B, Nanus DM. Neutral endopeptidase inhibits prostate cancer cell migration by blocking focal adhesion kinase (FAK) signaling. J Clin Inv 2000:106;1399-1407.
51. Sumitomo M, Shen R, Goldberg JS, Dai J, Navarro D, Nanus DM. Neutral endopeptidase promotes phorbol ester-induced apoptosis in prostate cancer cells by inhibiting neuropeptide-induced protein kinase C degradation. Cancer Res 2000:60;6590-6596.
52. Shen R, Sumitomo M, Dai J, Hardy DO, Navarro D, Usmani B, Papandreou CN, Hersh LB, Shipp MA, Freedman LP, Nanus DM. Characterization of two androgen-response regions in the human neutral endopeptidase gene. Mol Cell Endocrinology 2000:170;131-142.
53. Guo X, Nanus DM, Riz A, Rando RR, Bok, D, Gudas LJ. Reduced levels of retinyl esters and vitamin A content in human renal cancers. Cancer Res 2001:61;2774-2781.
54. Sumitomo M, Milowsky M, Shen R, Navarro D, Dai J, Asano T, Hayakawa M, Nanus DM. Neutral endopeptidase inhibits neuropeptide-mediated transactivation of the insulin-like growth factor receptor-Akt cell survival pathway. Cancer Res 2001:61;3294-3298.
55. Dai J, Shen R, Sumitomo M, Goldberg JS, Geng Y, Navarro D, Xu S, Koutcher J, Garzotto M, Powell CT, Nanus DM. Tumor suppressive effects of neutral endopeptidase in androgen- independent prostate cancer cells. Clin Cancer Res 2001:7;1370-1377.
56. Milowsky MI, Rosmarin AS, Tickoo SK, Papanicolaou NI, Nanus DM. Active chemotherapy for collecting duct carcinoma of the kidney: Case report and review of the literature. Cancer 2002:94;111-116.
57. Guo X, Knudsen BS, Peehl DM, Ruiz A, Bok D, Rando RR, Rhim JS, Nanus DM, Gudas LJ. Retinol metabolism and lecithin:retinol acyltransferase (LRAT) levels are reduced in cultured human prostate cancer cells and tissue specimens. Cancer Res 2002:62;1654-1661.
58. Dai J, Shen R, Sumitomo M, Stahl R, Navarro D, Gershengorn MC, Nanus DM. Synergistic activation of the androgen receptor by bombesin and low-dose androgen. Clin Cancer Res 2002;8:2399-2405.
59. Goldberg JS, Vargas M, Rosmarin AS, Papanicoloau N, Milowsky MI, Gudas LJ, Shelton G, Feit K, Petrylak D, Nanus DM. Phase I trial of interferon α-2b and liposome encapsulated all-trans retinoic acid in the treatment of advanced renal cell carcinoma. Cancer 2002;95:1220-1227.
60. Knudsen BS, Gmyrek GA, Inra J, Scherr DS, Vaughan ED, Nanus DM, Kattan MW, Gerald WL, Vande Woude GF. High Expression of the Met Receptor in Prostate Cancer Metastasis to Bone. Urology 2002;60:1113-7.
61. Shen R, Milowsky MI, Ozaki N, Navarro D, Sumitomo M, Xu Y, Nanus DM. Detection of the p110 subunit of phosphatidylinositol 3-kinase complexed with neutral endopeptidase. Anticancer Res 2002;22:2533-8.
62. Bander NH, Trabulsi EJ, Kostakoglu L, Yao D, Vallabhajosula S, Smith-Jones P, Joyce MA,
Milowsky MI, Nanus DM, Goldsmith S. Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. J Urol 2003;170:1717-1721.
63. Zhan HC, Gudas LJ, Bok D, Rando R, Nanus DM, Tickoo SK. Differential expression of the enzyme which esterifies retinol, lecithin:retinol acyltransferase, in subtypes of human renal cancer and normal kidney. Clin Cancer Res 2003;9:4897-905.
64. Nanus DM, Milowsky MI, Kostakoglu L, Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, Bander NH. Clinical utility of monoclonal antibody HuJ591 therapy: Targeting prostate specific membrane antigen (PSMA). J Urol 2003;170:S84-S89.
65. Carroll PR, Benaron DA, Blackledge G, Coakley FV, D'Amico AV, Higano CS, Iversen P, Kattan M, Nanus DM, Nelson JB, Oh WK, Roach M 3rd, Sellers WR, Smith MR, McMann MC, Kantoff PW. Third international conference on innovations and challenges in prostate cancer: Prevention, detection and treatment. J Urol 2003;170:S3-5.
66. Sumitomo M, Asano T, Asakuma J, Asano T, Nanus DM, Hayakawa M. Chemosensitization of androgen-independent prostate cancer with neutral endopeptidase. Clin Cancer Res 2004;10:260-266.
67. Sumitomo M, Iwase A, Navarro D, Zheng R, Kaminetzky D, Shen R, Georgescu M-M, Nanus DM. Synergy in tumor suppression by direct interaction of neutral endopeptidase with PTEN. Cancer Cell 2004;5:67-78.
68. Marchio S, Lahdenranta J, Schlingemann RO, Valdembri D, Wesseling P, Arap MA, Hajitou A, Ozawa M, Trepel M, Giordano R, Nanus DM, Dijkman HBPM, Oosterwijk E, Sidman RL, Cooper MD, Bussolino F, Pasqualini R, Arap W. Aminopeptidase A is a functional vascular target in angiogenic blood vessels. Cancer Cell 2004:5:151-162.
69. Iwase A, Shen R, Navarro D, Nanus DM. Direct binding of neutral endopeptidase 24.11 to ezrin/radixin/moesin (ERM) proteins competes with the interaction of CD44 with ERM proteins. J Biol Chem 2004:279:11898-905.
70. Boorjian S, Tickoo SK, Mongan NP, Yu H, Bok D, Rando RR, Nanus DM, Scherr DS, Gudas LJ. Decrease of lecithin:retinol acyltransferase (LRAT) expression correlates with increased pathologic tumor stage in bladder cancer. Clin Cancer Res 2004;10:3429-37.
71. Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ, Bander NH. Phase I trial results of Yttrium-90 labeled anti-prostate specific membrane antigen monoclonal antibody J591 in the treatment of patients with recurrent prostate cancer. J Clin Onc 2004; 22:2522-31.
72. Osman I, Taneja S, Yee H, Nobert C, Chang C, Wieczorek R, Kang M, Levinson B, Zeleniuch- Jacqoutte A, Nanus DM. Neutral endopeptidase (NEP) protein expression and prognosis in localized prostate cancer. Clin Cancer Res 2004;10:4096-100.
73. Kelly JD, Dai J, Eschwage P, Golberg JH, Duggan BP, Williamson KE, Bander NH, Nanus DM. Down regulation of Bcl-2 sensitizes interferon resistant renal cancer cells to Fas. Br J Cancer 2004;91:164-70.
74. Nanus DM, Garino A, Milowsky MI, Larkin M, Dutcher JP. Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma. Cancer 2004;101:1545-1551.
75. Vallabhajosula S, Kuji I, Klaus HA, Konishi S, Kostakoglu L, Kothari PA, Milowsky MI, Nanus DM, Bander NH, Goldsmith SJ. Pharmacokinetics and Biodistribution of 111In and 177Lu Labeled J591 Antibody Specific to Prostate Specific Membrane Antigen: Prediction of 90Y-J591 Radiation Dosimetry Based on 111In or 177Lu? J Nuc Med 2005;46(4):634-41..
76. Vallabhjosula S, Goldsmith SJ, Hamacher KA, Kostakoglu L, Konishi S, Milowsky MI, Nanus DM, Bander NH. Prediction of Myelotoxicity Based on Bone Marrow Radiation Absorbed Dose: Radioimmunotherapy Studies using 90Y and 177Lu Labeled J591 Antibodies Specific to Prostate Specific Membrane Antigen (PSMA). J Nuc Med 2005;46(5):850-8.
77. Boorjian S, Scherr DS, Mongan NP, Zhuang Y, Nanus DM, Gudas LJ. Retinoid receptor mRNA expression profiles in human bladder cancer specimens. Int J Oncol. 2005;26(4):1041-8.
78. Touma SE, Goldberg JS, Moench P, Guo X, Tickoo SK, Gudas LJ, Nanus DM. Retinoic acid and the histone deacetylase inhibitor trichostatin a inhibit the proliferation of human renal cell carcinoma in a xenograft tumor model. Clin Cancer Res. 2005;11(9):3558-66.
79. Bander NH, Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Onc 2005;23:4591- 601.
80. Sumitomo M, Shen R, Nanus DM. Involvement of neutral endopeptidase in neoplastic progression. Biochim Biophys Acta 2005;1751:52-9.
81. Vallabhajosula S, Goldsmith SJ, Kostakoglu L, Milowsky MI, Nanus DM, Bander NH. Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled J591 monoclonal antibodies: Effect of multiple treatments on myelotoxicity. Clin Cancer Res. 2005;11:7195s-200s
82. Raman JD, Mongan NP, Liu L, Tickoo SK, Nanus DM, Scherr DS, Gudas LJ. Decreased expression of the human stem cell marker, rex-1 (zfp-42), in renal cell carcinoma. Carcinogenesis. 2005, 27:499-507.
83. Gong J, Zhu J, Goodman O, Pestell RG, Schlegel PN, Nanus DM, Shen R. Activation of p300 histone acetyltransferase activity and acetylation of the androgen receptor by bombesin in prostate cancer cells. Oncogene 2006, 30;25:2011-21.
84. Horiguchi A, Sumitomo M, Asakuma J, Asano T, Zheng R, Asano T, Nanus DM, Hayakawa M. Leptin promotes invasiveness of murine renal cancer cells via extracellular signal-regulated kinases and rho dependent pathway. J Urol. 2006;176:1636-41.
85. Horiguchi A, Sumitomo M, Asakuma J, Asano T, Zheng R, Asano T, Nanus DM, Hayakawa M. Increased serum leptin levels and over expression of leptin receptors are associated with the invasion and progression of renal cell carcinoma. J Urol. 2006, 176:1631-5.
86. Zheng R, Iwase A, Shen R, Goodman OB, Sugimotoψ N, Takuwaψ Y, Lerner DJ, Nanus DM. Bombesin receptors activate RhoA through two non-redundant RGS-domain Rho GEFs in prostate cancer cells. Oncogene 2006;25:5942-52.
87. Zheng R, Shen R, Goodman OB, Nanus DM. Androgen regulation of the neutral endopeptidase gene. Mol Cell Endo 2006;259:10-21.
88. Goodman, OB Jr, Febbraio M, Simantov R, Shen R, Silverstein RL, Nanus DM. Neutral endopeptidase functions as a negative regulator of angiogenesis through proteolytic cleavage of basic fibroblast growth factor (FGF-2). J Biol Chem 2006;281:33597-605.
89. Osman I, Dai J, Sorhaindo L, Navarro D, Taneja SS, Lee P, Christos P, Shen R, Nanus DM. Loss of neutral endopeptidase and Akt activation is associated with prostate cancer progression. Cancer 2006;107:2628-36.
90. Velazquez EF, Yancovitz M, Pavlick A, Berman R, Shapiro R, Bogunovic D, O'Neill D, Yu Y-L, Spira J, Christos PJ, Mazumdar M, Nanus DM, Liebes L, Bhardwaj N, Polsky D, Osman I. Clinical Relevance of Neutral Endopeptidase (NEP/CD10) in Melanoma. J Translational Med 2007;5:2.
91. Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ, Ross JS, Bander NH. Vascular targeted therapy with anti-PSMA monoclonal antibody J591 in patients with advanced solid tumor malignancies, J Clin Onc 2007;25:540-7
92. Tewari A, Divine G, Chang P, Shemtov MM, Milowsky M, Nanus D, Menon M. Long-term survival in men with high grade prostate cancer: a comparison between conservative treatment, radiation therapy and radical prostatectomy--a propensity scoring approach. J Urol. 2007;177:911-5.
93. Hussain M, MacVicar GR, Petrylak D, Dunn R, Vaishampayan U, Lara, Jr PN, Chatta G, Nanus DM, Glode LM, Trump D, Chen H, Smith DC. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced Her-2/neu positive urothelial carcinoma: Results of a multi-center phase II NCI trial. J Clin Onc 2007, in press.
94. Horiguchi A, Zheng R, Goodman OB, Shen R, Guan H, Hersh LB, Nanus DM. Lentiviral vector neutral endopeptidase gene transfer suppresses prostate cancer tumor growth. Cancer Gene Therapy 2007;14:583-9..
95. David KA, Milowsky MI, Ritchey J, Carroll PR, Nanus DM. Low incidence of perioperative chemotherapy in stage III bladder cancer (1998-2003): A report from the National Cancer Data Base. J Urol 2007, in press.
96. Zhu J, Gong JY, Goodman OB, Cartegni L, Nanus DM, Shen R. Bombesin attenuates pre-mRNA splicing of glucocorticoid receptor by regulating the expression of serine-arginine protein p30c (SRp30c) in prostate cancer cells. Biochim Biophys Acta 2007, in press.
97. Boorjian SA, Milowsky MI, Kaplan J, Albert M, Rosario C, Coll DM, Mongan NP, Shelton G, Petrylak D, Gudas LJ, Nanus DM. Phase I/II clinical trial of interferon alpha 2b and weekly liposome-encapsulated all-trans retinoic acid in patients with advanced renal cell carcinoma J Immunother 2007, in press.
98. Goodman OG, Barwe SP, Ritter B, McPherson PS, Vaskos AJ, Keens JH, Nanus DM, Bander NH, Rajeskaran AK. Interaction of prostate specific membrane antigen with clathrin and the adaptor protein complex-2. Int J Oncol 2007, in press.
99. Horiguchi A, Chen DYT, Goodman OB, Zheng R, Shen R, Guan H, Hersh LB, Nanus DM.
Neutral endopeptidase inhibits prostate cancer tumorigenesis by reducing FGF-2-mediated angiogenesis. Prostate Cancer Prostatic Dis. 2007, in press.
B. Books, Chapters, Reviews, Editorials
1. Nanus DM and Bosl GB. Systemic chemotherapy in the management of bladder cancer. Cancer Treat Res 1989;46:143-158.
2. Bander NH, Gastl G, Nanus DM, Pfeffer LM, Finstad CL, Albino AP. Anti-proliferative and antitumor effect of -interferon in renal cell carcinoma: Correlation with the expression of a kidney associated differentiation glycoprotein in Basic and Clinical Research on Renal Cell Carcinoma, Staehler G, Pomer S, eds. Springer-Verlag, Berlin, 1992, 115-120.
3. Nanus DM and Albino AP. Oncogene induced transformation of human kidney proximal tubule cells in Renal Cell Carcinoma: Immunotherapy and Cellular Biology, Klein EA, Bukowski RM, Finke JH, eds. Marcel Dekker, Inc., New York, 1993, 53-65.
4. Bander NH, Gastl GA, Nanus DM, Finstad CL, Albino AP, Pfeffer LM. Antiproliferative and antitumor effect of interferon- in renal cell carcinoma in Renal Cell Carcinoma: Immunotherapy and Cellular Biology, Klein E, Bukowski RM, Finke J, eds. Marcel Dekker, Inc., New York, 1993, 85-91.
5. Nanus DM and Walker CL. Experimental Models of Renal Cancer in Principles and Practice of Genitourinary Oncology, Raghavan D, Scher HI, Leibel SA, Lange P, eds. J.B. Lippincott Co., Philadelphia, 1996, 779-785.
6. Motzer RJ, Russo P, Nanus DM, Berg W. Renal cell carcinoma in Current Problems in Cancer, Ozols RF, ed., Mosby, St. Louis, 1997;21:185-232.
7. Nanus DM, Papandreou CN, Albino AP. Expression of cell-surface peptidases in neoplastic cells in Cell-surface Peptidases, Kenny J, Boustead CM, eds. Bios Scientific Publishers Ltd., Oxford, 1997, 353-369.
8. Motzer RJ, Bander NH, Nanus DM. Letter to the Editor. N Engl J Med 1997;336:810-811.
9. Motzer RJ, Schwartz P, Murray-Law T, Hoffman AD, Albino AP, Vlamis V, Nanus DM. Antitumor effect of interferon alfa-2a and 13 cis-retinoic Acid in renal cell carcinoma: Results of a Phase II Trial and in vitro Studies in Classic Papers and Current Comments: Highlights of Genitourinary Cancer Research, Vogelzang NJ ed. WB Saunders Co., Philadelphia, 1997;2:307-315.
10. Nanus DM and Gudas LJ. Retinoids and prostate cancer. Prostate J 2000:2;68-73.
11 Berg WJ, Divgi CR, Nanus DM, Motzer RJ. Novel investigative approaches for advanced renal cell carcinoma. Semin Oncol 2000;27:234-239.
12. Nanus DM. New treatment approaches for metastatic renal cell carcinoma. Curr Oncol Rep 2000;2:417-422.
13. Nanus DM and Engelstein D. Orthotopic Model of Renal Cell Carcinoma in Renal Cancer Methods and Protocols, Mydlo JH, ed. Humana Press Inc., Totowa, 2001;53:245-253.
14. Nanus DM. Introduction to Urologic Oncology Series. Cancer Invest 2001:19;76.
15. Pastore RD, Pfeffer LM, Nanus DM. Renal cell carcinoma and interferon at the millenium. Cancer Invest 2001:19:281-291.
16. Nanus DM. Renal cell carcinoma (Book Review). Cancer Invest 2001;19:343.
17. Nanus DM, Shen R, Dai J, Sumitomo M. Neutral endopeptidase and other peptidases such as aminopeptidase A and dipeptidyl peptidase IV in the development and progression of cancer in Cell Surface Aminopeptidases: Basic and Clinical Aspects, Mizutani S, Turner AJ, Nomura S, Ino K (eds), Amsterdam, Elsevier Science 2001:119-128.
18. Milowsky MI and Nanus DM. Advanced Renal Cell Carcinoma. Curr Treat Options Oncol 2001;2:437-45.
19. Milowsky MI, Nanus DM. Estramustine plus a taxane for advanced prostate cancer: The new standard therapy? Cancer Invest 2002:20;849-850.
20. Yao D, Trabulsi EJ, Kostakoglu L, Vallabhajosula S, Joyce MA, Nanus DM, Milowsky M, Liu H, Goldsmith S. The utility of monoclonal antibodies in the imaging of prostate cancer. Semin Urol Oncol. 2002;20:211-8.
21. Milowsky MI, Del Pizzo JJ, Nanus DM. Kidney Cancer in Atlas of Cancer, Markman M, ed, Lippincott Williams and Wilkins, Philadelphia, 2003;443-449.
22. Milowsky MI and Nanus DM. Chemotherapeutic Strategies for Renal Cell Carcinoma in Contemporary Management of Renal Cell Carcinoma, Taneja S匀Ⰰ 攀搀Ⰰ 圀⸀䈀⸀ 匀愀甀渀搀攀爀猀 䌀漀⸀Ⰰ ☀渀戀猀瀀㬀☀渀戀猀瀀㬀☀渀戀猀瀀㬀倀栀椀氀愀搀攀氀瀀栀椀愀Ⰰ 唀爀漀氀 䌀氀椀渀 一 䄀洀 ㈀ ㌀㨀㌀ 㬀㘀 ⴀ㘀 㤀⸀ 㰀戀爀⼀㸀㰀戀爀⼀㸀㈀㌀⸀ 䈀愀渀搀攀爀 一䠀Ⰰ 一愀渀甀猀 䐀䴀Ⰰ 䴀椀氀漀眀猀欀礀 䴀䤀Ⰰ 䬀漀猀琀愀欀漀最氀甀 䰀Ⰰ 嘀愀氀氀愀戀愀栀愀樀漀猀甀氀愀 匀Ⰰ 䜀漀氀搀猀洀椀琀栀 匀䨀⸀ ☀渀戀猀瀀㬀☀渀戀猀瀀㬀☀渀戀猀瀀㬀吀愀爀最攀琀攀搀 猀礀猀琀攀洀椀挀 琀栀攀爀愀瀀礀 漀昀 瀀爀漀猀琀愀琀攀 挀愀渀挀攀爀 眀椀琀栀 愀 洀漀渀漀挀氀漀渀愀氀 愀渀琀椀戀漀搀礀 琀漀 瀀爀漀猀琀愀琀攀 猀瀀攀挀椀昀椀挀 ☀渀戀猀瀀㬀☀渀戀猀瀀㬀☀渀戀猀瀀㬀洀攀洀戀爀愀渀攀 愀渀琀椀最攀渀⸀ 匀攀洀椀渀 伀渀挀 ㈀ ㌀㬀㌀ 㨀㘀㘀㜀ⴀ㘀㜀㜀⸀㰀戀爀⼀㸀 㰀戀爀⼀㸀㈀㐀⸀ 一愀渀甀猀 䐀䴀⸀ 伀昀 倀攀瀀琀椀搀攀猀 愀渀搀 倀攀瀀琀椀搀愀猀攀猀㨀 吀栀攀 爀漀氀攀 漀昀 挀攀氀氀ⴀ猀甀爀昀愀挀攀 瀀攀瀀琀椀搀愀猀攀猀 椀渀 挀愀渀挀攀爀⸀ 䌀氀椀渀 ☀渀戀猀瀀㬀☀渀戀猀瀀㬀☀渀戀猀瀀㬀䌀愀渀挀攀爀 刀攀猀 ㈀ ㌀㬀㤀㨀㘀㌀ 㜀ⴀ㘀㌀ 㤀
